An interdisciplinary approach aiding the diagnosis of primary progressive aphasia: A case report

Shigaeff, Nadia; Zanetti, Mayra; Tierno, Sibelle de Almeida; Tommaso, Ana Beatriz Galhardi Di; Marques, Thaís Cristina; Franco, Frederico Souzalima Caldoncelli

doi:10.1590/1980-57642016dn11-010014

Cited by 3 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the field of pharmacological interventions, to date, no medications have been shown to improve or stabilize cognitive deficits in patients with PPA [ 29 ]. Indeed, clinical trials on patients with FTD and controlled trials on PPA patients with bromocriptine [ 30 ] and memantine [ 31 ] have not demonstrated any efficiency.…”

Section: Discussionmentioning

confidence: 99%

The course of primary progressive aphasia diagnosis: a cross-sectional study

et al. 2022

View full text Add to dashboard Cite

Background The primary progressive aphasia (PPA) diagnosis trajectory is debated, as several changes in diagnosis occur during PPA course, due to phenotype evolution from isolated language alterations to global cognitive impairment. The goal of the present study, based on a French cohort, was to describe the demographics and the evolution of subjects with (PPA) in comparison with Alzheimer’s disease (AD) on a period of 7 years. Methods We conducted a repeated cross-sectional study. The study population comprised individuals with PPA and AD diagnosis (N=167,191) from 2010 to 2016 in the French National data Bank (BNA). Demographic variables, MMSE scores, diagnosis status at each visit and prescribed treatments were considered. Results From 2010 to 2016, 5186 patients were initially diagnosed with PPA, 162,005 with AD. Compared to AD subjects, significant differences were found concerning age (younger at first diagnosis for PPA), gender (more balanced in PPA), education level (higher in PPA) and MMSE score (higher of 1 point in PPA). Percentage of pending diagnosis, delay between first consultation and first diagnosis and the number of different diagnoses before the diagnosis of interest were significantly higher in PPA group compared to AD group. Pharmacological and non-pharmacological treatments were significatively more recommended following PPA than AD diagnosis. Conclusion This study improves the knowledge of PPA epidemiology and has the potential to help adopting appropriate public health service policies. It supports the hypothesis that PPA is diagnosed later than AD. The PPA diagnosis increases the prescription of non-pharmacological treatments, especially speech and language therapy (SLT) that is the main treatment available and most effective when at the initial stage. Trial registration ClinicalTrials.gov identifier NCT03687112

show abstract

Section: Discussionmentioning

confidence: 99%

The course of primary progressive aphasia diagnosis: a cross-sectional study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In the eld of pharmacological interventions, to date, no medications have been shown to improve or stabilize cognitive de cits in patients with PPA [27]. Indeed, clinical trials on patients with FTD and controlled trials on PPA patients with bromocriptine[28] and memantine [29] have not demonstrated any e ciency.…”

Section: Discussionmentioning

confidence: 99%

The Course of Primary Progressive Aphasia Diagnosis : A Cross-Sectional Study.

Mouton

Plonka

Fabre

et al. 2021

Preprint

View full text Add to dashboard Cite

BackgroundThe Primary Progressive Aphasia (PPA) diagnosis trajectory is debated, as several changes in diagnosis occur during PPA course, due to phenotype evolution from isolated language alterations to global cognitive impairment.The goal of the present study, based on a French cohort was to describe the demographics and the evolution of subjects with (PPA) in comparison with Alzheimer Disease (AD) on a period of seven years. MethodsWe conducted a repeated cross-sectional study. The study population comprised individuals with PPA and AD diagnosis (N=167191) from 2010 to 2016 in the French National data Bank (BNA). Demographic variables, MMSE scores, diagnosis status at each visit and prescribed treatments were considered.ResultsFrom 2010 to 2016, 5186 patients were initially diagnosed with PPA, 162005 with AD. Compared to AD subjects, significant differences were found concerning: age (younger at first diagnosis for PPA), gender (more balanced in PPA), education level (higher in PPA) and MMSE score (higher in PPA). Percentage of pending diagnosis, delay between first consultation and first diagnosis and the number of different diagnoses before the diagnosis of interest were significantly higher in PPA group compared to AD group. Pharmacological and non-pharmacological treatments were significatively more recommended following PPA than AD diagnosis.ConclusionThis study improves the knowledge of PPA epidemiology and has the potential to help adopting appropriate public health service policies. It supports the hypothesis that PPA is diagnosed later than AD. The PPA diagnosis increases the prescription of non-pharmacological treatments, especially speech and language therapy (SLT) that is the main treatment available and most effective when at the initial stage.Trial registrationClinicalTrials.gov identifier NCT03687112

show abstract